Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOSYN 10% (PH6) vs CHOLESTYRAMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Primary hypercholesterolemia (Type IIa hyperlipoproteinemia),Pruritus associated with partial biliary obstruction and primary biliary cirrhosis,Pseudomembranous colitis (Clostridioides difficile infection)-associated diarrhea (adjunctive),Diarrhea associated with bile acid malabsorption,Eczema (off-label),Hyperoxaluria (off-label)
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
Cholestyramine is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Not applicable; cholestyramine is not absorbed and does not bind to plasma proteins.
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
Not applicable; due to lack of systemic absorption, Vd is essentially zero.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
Oral: <0.1% (negligible systemic absorption); cholestyramine acts locally in the gastrointestinal tract.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
No dosage adjustment required for renal impairment; caution in patients with severe renal disease due to risk of hyperchloremic metabolic acidosis
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Use with caution in cirrhosis or cholestatic disorders; no specific Child-Pugh guidelines; monitor for increased bleeding risk due to vitamin K malabsorption
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
Initial 240 mg/kg/day (approximately 0.625 g/kg/day) divided into 2-3 doses, titrated based on response; maximum 8 g/day
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
Start at low end of dosing range (4 g/day) due to increased risk of constipation and fecal impaction; monitor for electrolyte disturbances and drug interactions
None
No FDA black box warning.
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
May reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be required.,May impair absorption of other medications (e.g., digoxin, warfarin, thyroid hormones); administer at least 4-6 hours before or after cholestyramine.,May cause hyperchloremic metabolic acidosis, especially in pediatric patients.,May exacerbate hemorrhoids due to constipation.,Use with caution in patients with phenylketonuria (contains aspartame in some formulations).
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
Complete biliary obstruction (unable to excrete bile into intestine),Hypersensitivity to cholestyramine or any component,Phenylketonuria (if product contains aspartame)
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
Cholestyramine may interfere with absorption of fat-soluble vitamins (A, D, E, K). Long-term use may require supplementation. Administer with meals to bind bile acids. High-fiber foods may help counteract constipation. Avoid taking cholestyramine close to other medications or foods that require optimal absorption.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. However, due to potential maternal fat-soluble vitamin deficiency (A, D, E, K) caused by the drug, indirect fetal risk exists, especially in the first trimester for neural tube defects (vitamin A) and second/third trimester for coagulation (vitamin K). Use only if clearly needed and monitor maternal vitamin levels.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
Cholestyramine is not excreted into breast milk due to negligible systemic absorption. It is considered compatible with breastfeeding, as no adverse effects on the nursing infant have been reported. M/P ratio is not applicable. Monitor infant for signs of vitamin deficiency if mother uses high doses long-term.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
No dose adjustment is needed for pregnancy because cholestyramine is not absorbed systemically. However, consider increasing the dose if concurrent vitamin supplementation is used, as cholestyramine may bind and reduce absorption of fat-soluble vitamins. Administer vitamins at least 1 hour before or 4-6 hours after cholestyramine. Monitor for adequate therapeutic effect; dose may be adjusted based on clinical response (e.g., pruritus or diarrhea control).
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
Cholestyramine is a bile acid sequestrant used to lower LDL cholesterol by binding bile acids in the intestine, increasing their fecal excretion, and upregulating hepatic LDL receptors. It is also used for pruritus associated with cholestasis and for diarrhea due to bile acid malabsorption. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine, as it can impair absorption of many drugs (e.g., warfarin, digoxin, thyroid hormones). Monitor for constipation, which is common and can be severe; increase fiber and fluid intake. Cholestyramine can cause hypertriglyceridemia; check triglycerides before and during therapy. It may reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation with long-term use.
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
Take this medication exactly as prescribed, usually 2-4 times daily with meals or at bedtime.,Mix the powder with at least 4-8 ounces of water, fruit juice, or non-carbonated beverage; stir well and drink immediately. Do not swallow dry powder.,Do not take other medications or supplements within 1 hour before or 4-6 hours after taking cholestyramine, as it can prevent their absorption.,Increase fluid and dietary fiber intake to help prevent constipation. Notify your doctor if constipation becomes severe or if you have stomach pain.,Inform your doctor if you develop unusual bleeding or bruising, which may indicate vitamin K deficiency.,Cholestyramine may increase blood triglyceride levels; your doctor will monitor your blood lipid profile.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOSYN 10% (PH6) vs CHOLESTYRAMINE, answered by our medical review team.
AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. CHOLESTYRAMINE is a Bile Acid Sequestrant that works by Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOSYN 10% (PH6) and CHOLESTYRAMINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. The standard adult dose of CHOLESTYRAMINE is: 4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOSYN 10% (PH6) and CHOLESTYRAMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. CHOLESTYRAMINE is classified as Category C. Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. Howe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.